Table 1.
Baseline VCA-IgA distribution in 18,286 non-nasopharyngeal carcinoma (NPC) participants by age and sex
| Sex | Age (years) | No. of participants | VCA-IgA [cases (%)] | χ2 | P | ||||
|---|---|---|---|---|---|---|---|---|---|
| – | 1:5 | 1:10 | 1:20 | ≥1:40 | |||||
| Male | 30–39 | 3063 | 2861 (93.4) | 108 (3.5) | 69 (2.3) | 16 (0.5) | 9 (0.3) | ||
| 40–49 | 2196 | 2022 (92.1) | 68 (3.1) | 76 (3.5) | 23 (1.0) | 7 (0.3) | 11.844 | 0.001 | |
| 50–59 | 1740 | 1584 (91.0) | 73 (4.2) | 57 (3.3) | 16 (0.9) | 10 (0.6) | |||
| Female | 30–39 | 5541 | 5225 (94.3) | 139 (2.5) | 129 (2.3) | 27 (0.5) | 21 (0.4) | ||
| 40–49 | 3070 | 2855 (93.0) | 93 (3.0) | 83 (2.7) | 24 (0.8) | 15 (0.5) | 15.475 | 0.000 | |
| 50–59 | 2676 | 2463 (92.0) | 96 (3.6) | 71 (2.7) | 30 (1.1) | 16 (0.6) | |||
VCA-IgA immunoglobulin A (IgA) antibodies against viral capsid antigen of Epstein–Barr virus (EBV)